Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Non-Current Assets (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Non-Current Assets for 4 consecutive years, with $30.2 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 65.95% to $30.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $123.3 million through Dec 2025, up 98.35% year-over-year, with the annual reading at $30.2 million for FY2025, 65.95% up from the prior year.
  • Non-Current Assets for Q4 2025 was $30.2 million at Phathom Pharmaceuticals, down from $32.5 million in the prior quarter.
  • The five-year high for Non-Current Assets was $32.5 million in Q3 2025, with the low at $3.3 million in Q1 2022.
  • Average Non-Current Assets over 4 years is $15.0 million, with a median of $13.9 million recorded in 2024.
  • Peak annual rise in Non-Current Assets hit 288.41% in 2024, while the deepest fall reached 10.81% in 2024.
  • Over 4 years, Non-Current Assets stood at $4.3 million in 2022, then skyrocketed by 281.81% to $16.4 million in 2023, then increased by 10.81% to $18.2 million in 2024, then surged by 65.95% to $30.2 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $30.2 million, $32.5 million, and $31.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.